Here, we report a mechanism by which MVs shed from breast cancer cells trigger an immediate and sustained activation of VEGFRs on endothelial cells that is insensitive to the inhibitory actions of VEGF antibodies like Bevacizumab. The gene discussed is VEGFA; the disease is breast cancer.